TP53 and ovarian carcinoma: After treatment with DZNep, an inhibitor of EZH2, the expression of EZH2 protein was decreased and of p21, p53 and RUNX3 was increased in ovarian cancer cells A2780, ES2 and SKOV3 (Figure S3J).